Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XENE, TEVA, SAVA, APGE, NUVL, and represent 27.91% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: SAVA (+$43M), NUVL (+$14M), ALKS (+$9.8M), Oruka Therapeutics (+$8.6M), VRDN (+$8.5M), WVE (+$8.4M), Omeros Corp (+$6.9M), ANAB (+$6.7M), XENE (+$5.9M), SPRY (+$5.8M).
- Started 18 new stock positions in ANAB, VSTM, NVAX, VYGR, TERN, Travere Therapeutics, SYRS, SPRY, SMMT, SAVA. GALT, Oruka Therapeutics, SLNO, RPTX, AADI, BMRN, ARVN, Adagio Med Hldgs.
- Reduced shares in these 10 stocks: , CERE (-$31M), Bridgebio Pharma (-$17M), BGNE (-$17M), Alnylam Pharmaceuticals Inc Note 1.000 9/1 (-$16M), CLDX (-$12M), APGE (-$10M), MORF (-$8.5M), INSM (-$6.1M), CRNX (-$5.9M).
- Sold out of its positions in ALXO, ABIO, Alnylam Pharmaceuticals Inc Note 1.000 9/1, BDTX, Bridgebio Pharma, CERE, DYN, ELEV, FULC, HLVX.
- Affinity Asset Advisors was a net seller of stock by $-217M.
- Affinity Asset Advisors has $733M in assets under management (AUM), dropping by -15.53%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 84 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals (XENE) | 6.1 | $45M | +15% | 1.1M | 39.37 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 5.9 | $43M | -7% | 2.4M | 18.02 |
|
| Cassava Sciences Put Option (SAVA) | 5.8 | $43M | NEW | 1.4M | 29.43 |
|
| Apogee Therapeutics (APGE) | 5.3 | $39M | -20% | 664k | 58.74 |
|
| Nuvalent Inc-a (NUVL) | 4.7 | $35M | +68% | 338k | 102.30 |
|
| Arcellx Common Stock (ACLX) | 4.6 | $33M | -13% | 400k | 83.51 |
|
| Alkermes SHS (ALKS) | 3.8 | $28M | +53% | 1.0M | 27.99 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.9 | $21M | -9% | 100k | 212.22 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.8 | $20M | -22% | 400k | 51.10 |
|
| Nurix Therapeutics (NRIX) | 2.6 | $19M | -5% | 860k | 22.47 |
|
| Vera Therapeutics Cl A (VERA) | 2.6 | $19M | +16% | 435k | 44.20 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.6 | $19M | -7% | 650k | 28.77 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 2.2 | $16M | +4% | 4.5M | 3.63 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.1 | $15M | -14% | 966k | 15.99 |
|
| Inozyme Pharma (INZY) | 2.0 | $15M | 2.8M | 5.23 |
|
|
| Spyre Therapeutics Com New (SYRE) | 2.0 | $15M | -2% | 498k | 29.41 |
|
| Omeros Corp Note 5.250% 2/1 (Principal) | 2.0 | $15M | +87% | 22M | 0.68 |
|
| Kura Oncology (KURA) | 1.8 | $13M | +5% | 688k | 19.54 |
|
| Coherus Biosciences Note 1.500% 4/1 (Principal) | 1.8 | $13M | +41% | 17M | 0.79 |
|
| Establishment Labs Holdings Ord (ESTA) | 1.7 | $13M | +30% | 290k | 43.27 |
|
| Miragen Therapeutics (VRDN) | 1.6 | $12M | +250% | 525k | 22.75 |
|
| Wave Life Sciences SHS (WVE) | 1.6 | $12M | +273% | 1.4M | 8.20 |
|
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 1.3 | $9.6M | +25% | 12M | 0.79 |
|
| Immunovant (IMVT) | 1.2 | $8.6M | -24% | 303k | 28.51 |
|
| Oruka Therapeutics | 1.2 | $8.6M | NEW | 350k | 24.51 |
|
| Rezolute Com New (RZLT) | 1.1 | $8.2M | -8% | 1.7M | 4.85 |
|
| Merus N V (MRUS) | 1.1 | $8.1M | +29% | 162k | 49.96 |
|
| Astria Therapeutics (ATXS) | 1.1 | $8.0M | -25% | 725k | 11.01 |
|
| Beigene Sponsored Adr (BGNE) | 1.1 | $7.9M | -68% | 35k | 224.51 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.1 | $7.8M | +11% | 472k | 16.60 |
|
| Bridgebio Pharma (BBIO) | 1.0 | $7.6M | +200% | 300k | 25.46 |
|
| Eliem Therapeutics (ELYM) | 1.0 | $7.6M | -10% | 1.5M | 5.09 |
|
| Axsome Therapeutics (AXSM) | 1.0 | $7.2M | 80k | 89.87 |
|
|
| Erasca (ERAS) | 0.9 | $6.8M | 2.5M | 2.73 |
|
|
| Geron Corporation (GERN) | 0.9 | $6.8M | 1.5M | 4.54 |
|
|
| Anaptysbio Inc Common Put Option (ANAB) | 0.9 | $6.7M | NEW | 200k | 33.50 |
|
| Perspective Therapeutics Com New (CATX) | 0.9 | $6.7M | -9% | 500k | 13.35 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $6.3M | +550% | 325k | 19.37 |
|
| Silverback Therapeutics Call Option (SPRY) | 0.8 | $5.8M | NEW | 400k | 14.50 |
|
| Vaxcyte (PCVX) | 0.8 | $5.7M | -33% | 50k | 114.27 |
|
| Arvinas Ord (ARVN) | 0.8 | $5.5M | NEW | 225k | 24.63 |
|
| Terns Pharmaceuticals (TERN) | 0.7 | $5.0M | NEW | 600k | 8.34 |
|
| Springworks Therapeutics (SWTX) | 0.6 | $4.7M | +110% | 148k | 32.04 |
|
| Cullinan Oncology (CGEM) | 0.6 | $4.4M | 264k | 16.74 |
|
|
| Travere Therapeutics Note 2.250% 3/0 (Principal) | 0.6 | $4.3M | NEW | 5.0M | 0.86 |
|
| Celldex Therapeutics Com New (CLDX) | 0.6 | $4.2M | -73% | 125k | 33.99 |
|
| Mineralys Therapeutics (MLYS) | 0.6 | $4.2M | +6% | 350k | 12.11 |
|
| Novavax Com New Call Option (NVAX) | 0.5 | $3.8M | NEW | 300k | 12.63 |
|
| Insmed Com Par $.01 (INSM) | 0.5 | $3.7M | -62% | 50k | 73.00 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.5 | $3.5M | 350k | 10.03 |
|
|
| Galectin Therapeutics Com New Put Option (GALT) | 0.5 | $3.3M | NEW | 1.2M | 2.75 |
|
| Nextcure (NXTC) | 0.4 | $3.2M | +36% | 2.3M | 1.37 |
|
| Summit Therapeutics Call Option (SMMT) | 0.4 | $3.1M | NEW | 140k | 21.90 |
|
| Savara (SVRA) | 0.4 | $3.0M | -54% | 700k | 4.24 |
|
| Nkarta (NKTX) | 0.4 | $2.9M | +225% | 650k | 4.52 |
|
| Mirum Pharmaceuticals (MIRM) | 0.4 | $2.9M | -51% | 75k | 39.00 |
|
| Immatics SHS (IMTX) | 0.4 | $2.9M | -16% | 250k | 11.41 |
|
| Syros Pharmaceuticals Com New Put Option (SYRS) | 0.4 | $2.7M | NEW | 1.2M | 2.15 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.4 | $2.6M | 250k | 10.45 |
|
|
| Context Therapeutics (CNTX) | 0.4 | $2.6M | -18% | 1.3M | 1.96 |
|
| Inari Medical Ord (NARI) | 0.3 | $2.5M | -70% | 60k | 41.24 |
|
| Roivant Sciences SHS (ROIV) | 0.3 | $2.3M | -42% | 202k | 11.54 |
|
| Kezar Life Sciences (KZR) | 0.3 | $1.9M | +42% | 2.5M | 0.77 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $1.9M | -39% | 301k | 6.30 |
|
| Tectonic Therapeutic (TECX) | 0.2 | $1.8M | 58k | 30.30 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $1.5M | +5% | 213k | 7.00 |
|
| Soleno Therapeutics (SLNO) | 0.2 | $1.3M | NEW | 25k | 50.49 |
|
| Aerovate Therapeutics (AVTE) | 0.2 | $1.3M | +200% | 600k | 2.09 |
|
| Q32 Bio (QTTB) | 0.2 | $1.2M | 28k | 44.62 |
|
|
| Verastem Com New (VSTM) | 0.2 | $1.2M | NEW | 400k | 2.99 |
|
| BioMarin Pharmaceutical (BMRN) | 0.1 | $1.1M | NEW | 15k | 70.29 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.1 | $907k | 223k | 4.06 |
|
|
| Puma Biotechnology (PBYI) | 0.1 | $638k | 250k | 2.55 |
|
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $596k | NEW | 173k | 3.44 |
|
| Kyverna Therapeutics (KYTX) | 0.1 | $586k | -40% | 120k | 4.89 |
|
| Adagio Med Hldgs | 0.1 | $550k | NEW | 213k | 2.58 |
|
| Immatics *w Exp 07/01/202 (IMTXW) | 0.1 | $431k | 187k | 2.30 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $426k | 45k | 9.46 |
|
|
| Voyager Therapeutics (VYGR) | 0.0 | $303k | NEW | 52k | 5.85 |
|
| Neurobo Pharmaceuticals (NRBO) | 0.0 | $283k | 89k | 3.17 |
|
|
| Genelux Corporation (GNLX) | 0.0 | $237k | 100k | 2.37 |
|
|
| Aadi Bioscience (AADI) | 0.0 | $97k | NEW | 47k | 2.06 |
|
| Promis Neurosciences Com New (PMN) | 0.0 | $38k | -88% | 31k | 1.25 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $5.3k | 75k | 0.07 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023
- Affinity Asset Advisors 2022 Q3 filed Nov. 14, 2022
- Affinity Asset Advisors 2022 Q2 filed Aug. 12, 2022
- Affinity Asset Advisors 2022 Q1 filed May 13, 2022
- Affinity Asset Advisors 2021 Q4 filed Feb. 11, 2022
- Affinity Asset Advisors 2021 Q3 filed Nov. 12, 2021
- Affinity Asset Advisors 2021 Q2 filed Aug. 13, 2021
- Affinity Asset Advisors 2021 Q1 filed May 14, 2021